STOCK TITAN

CollPlant Biotechnologies Ltd. - $CLGN STOCK NEWS

Welcome to our dedicated page for CollPlant Biotechnologies Ltd. news (Ticker: $CLGN), a resource for investors and traders seeking the latest updates and insights on CollPlant Biotechnologies Ltd. stock.

CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is a pioneering company in regenerative and aesthetic medicine, specializing in the 3D bioprinting of tissues and organs and medical aesthetics. The company's core technology is its recombinant human collagen (rhCollagen), produced through proprietary plant-based genetic engineering. CollPlant's innovative products address diverse fields of tissue repair, aesthetics, and organ manufacturing, marking a new era in regenerative medicine.

CollPlant's flagship rhCollagen bioink product line is optimized for 3D bioprinting applications, including drug discovery, tissue testing, and the development of transplantable tissues and organs. The company's unique Vergenix™ line includes a soft tissue repair matrix for tendinopathy treatment and a wound repair matrix that promotes rapid healing of acute and chronic wounds.

In the medical aesthetics market, CollPlant is advancing its regenerative breast implants and dermal fillers. The company has formed strategic partnerships, including a notable collaboration with AbbVie for the development of dermal and soft tissue fillers, triggering milestone payments and potential future royalties.

Recent achievements include the initiation of pre-clinical trials for regenerative breast implants and progress in large-animal studies demonstrating tissue regeneration and safety. In addition, CollPlant's advanced bioinks are facilitating the bio-fabrication of human tissues and organs in collaboration with industry leaders.

Financially, CollPlant reported significant revenue increases due to milestone payments and product sales, although it continues to invest in research and development to maintain its leading position in the market. The company's cash and cash equivalents provide a robust runway for at least two years of operation, supporting ongoing and future projects.

CollPlant's commitment to sustainability is reflected in its plant-based production process and adherence to Environmental, Social, and Governance (ESG) principles. The company joined the United Nations Global Compact to further its sustainable corporate governance goals.

Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) announced a major milestone with the successful bio-printing of 200cc commercial-size regenerative breast implants using its proprietary rhCollagen bioinks. The company also reported positive interim pre-clinical data from ongoing large-animal studies, showing promising tissue growth and neovascularization without adverse reactions. The implants are designed to regenerate breast tissue, potentially offering a safer alternative to synthetic silicone implants. Large-animal studies are ongoing, with results expected in Q4 2024 and Q1 2025, which will support future human trials and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
-
Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) reported its Q1 2024 financial results and provided a corporate update. The company initiated a new large-animal study for its 3D-bioprinted breast implants in December 2023, expected to conclude in June 2024. Q1 2024 GAAP revenue was $98,000, a decrease from $433,000 in Q1 2023. Costs of revenue increased to $545,000 from $325,000, resulting in a gross loss of $447,000 compared to a gross profit of $108,000 in Q1 2023. Net loss widened to $4.2 million from $3.7 million. The company also highlighted advancements in its Environmental, Social, and Governance (ESG) initiatives and recent patent approvals in the U.S., Brazil, Israel, and Australia. Cash and cash equivalents as of March 31, 2024, stood at $23.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
-
Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) announced the release of its financial results for the first quarter of 2024 on May 29, 2024, before U.S. market opening. The company will host a conference call and webcast the same day at 10:00 a.m. EDT to discuss these results and provide corporate updates.

U.S. investors can dial 1-877-407-9716, international investors can call 1-201-493-6779, and Israeli investors can dial 1-809-406-247 using Conference ID 13745964. Participants can avoid long wait times by using the Call me™ feature available 15 minutes prior to the call.

A live listen-only webcast will be available, with a replay accessible on the company's website for a period. Questions for management can be submitted via email to Dan Ferry at LifeSci Advisors up to 24 hours before the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) announces financial results for 2023, highlighting progress in dermal filler and regenerative breast implant programs. The company ended 2023 with $26.7 million in cash. Collaboration with AbbVie and Stratasys advanced, triggering milestone payments. Regenerative breast implants showed promise in large-animal studies, targeting a $2.9 billion market. Intellectual property gains and ESG efforts were also notable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
-
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) schedules conference call to discuss financial results for the full year of 2023 on April 4, 2024, at 10:00 a.m. U.S. EDT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
-
News
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) CEO Yehiel Tal highlights key achievements in 2023, including progress with AbbVie collaboration and Stratasys partnership. The company focuses on regenerative and aesthetic medicine, with a pipeline of innovative products like regenerative breast implants and gut-on-a-chip tissue model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) CEO to present at Octane Aesthetic Tech Forum on 3D Bioprinted Regenerative Breast Implants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) Initiates Pre-Clinical Trial for Regenerative Breast Implants, Aiming to Revolutionize the $2.6 Billion Market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
-
Rhea-AI Summary
CollPlant Biotechnologies (Nasdaq: CLGN) announced a $10 million milestone payment from partner AbbVie Inc., a $29 million cash runway, and financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.63%
Tags
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) to report Q3 2023 financial results on November 29, 2023, followed by a conference call and webcast. Investors can participate in the call using the provided dial-in information or the Call me™ feature. A live webcast will also be available, and questions for management can be submitted in advance via email.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags

FAQ

What does CollPlant Biotechnologies Ltd do?

CollPlant specializes in regenerative and aesthetic medicine, focusing on 3D bioprinting of tissues and organs, and medical aesthetics.

What is rhCollagen?

rhCollagen is CollPlant's proprietary recombinant human collagen produced using plant-based genetic engineering technology.

What are CollPlant's main products?

CollPlant's products include rhCollagen bioinks for 3D bioprinting, Vergenix soft tissue repair and wound repair matrices, and regenerative breast implants.

What are the recent achievements of CollPlant?

CollPlant initiated pre-clinical trials for regenerative breast implants, progressed in large-animal studies, and received milestone payments from AbbVie.

Who are CollPlant's strategic partners?

Key partners include AbbVie for dermal and soft tissue fillers and Stratasys for bio-fabrication of tissues and organs.

Where does CollPlant operate?

CollPlant operates primarily in the United States, Canada, Europe, and Israel.

What are CollPlant's financial highlights?

CollPlant reported significant revenue increases, mainly from milestone payments and product sales, and maintains a strong cash position.

How is CollPlant contributing to sustainability?

CollPlant uses plant-based genetic engineering for its products, reduces environmental impact, and follows ESG principles, including joining the UN Global Compact.

What is the market potential for CollPlant's products?

CollPlant's products target large markets in tissue repair, medical aesthetics, and organ manufacturing, with ongoing development and commercialization efforts.

How can investors participate in CollPlant's conference calls?

Investors can join conference calls using the provided dial-in numbers or access live webcasts through the company's investor relations website.

CollPlant Biotechnologies Ltd.

Nasdaq:CLGN

CLGN Rankings

CLGN Stock Data

58.76M
7.82M
10.16%
12.23%
0.09%
Surgical Appliance and Supplies Manufacturing
Manufacturing
Link
United States of America
P O Box 4132